Merck’s Experimental Pneumonia Vaccine Hits the Mark in Two Phase III Studies

Merck’s investigational pneumonia vaccine, V114, hit the mark in two Phase III studies, including one involving adult HIV patients.

V114, Merck’s investigational 15-valent pneumococcal conjugate vaccine, was assessed in two late-stage studies.